Drug lobby aims to shake up how medicines are paid for; Where does J&J's new drug fit in the crowded HIV market?; 5 drugs to watch as biotechs report Q2; FDA seeks to make more drugs available over the counter
To meet the growing need for precision in tumor treatment, molecular profiling is becoming more complex. Gain expert insights into this new form of precision oncology treatment.
Learn more→
A new deal keeps Mylan's copycat drug at bay until mid-2023, making it more likely AbbVie's top-seller will enjoy several more years without generic rivals.
The pharma's four-drug tablet is heading to market, but what kind of foothold it can carve out given the wide variety of already available drugs is unclear.
Our mission is to provide busy execs like you with an overview of the BioPharma industry in 60 seconds. BioPharma Dive: Marketing is a product of Industry Dive. View other Industry Dive publications.
This email is optimized for display on mobile phones. BioPharma Dive: Marketing is a product of Industry Dive, Inc.. 1575 Eye St NW, 4th Floor, Washington, DC 20005. We value your privacy. We won't share your email address with anyone else without your permission. This message was sent to [email protected]. You can unsubscribe anytime. See our full privacy policy.